Clinical trial
An Open-Label, Single Arm Phase II Study of Nivolumab in Combination With Ipilimumab in Subjects With Advanced Neuroendocrine Tumors
NCT03420521 is registered in ClinicalTrials.gov with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Single Arm Phase II Study of Nivolumab in Combination With Ipilimumab in Subjects With Advanced Neuroendocrine Tumors
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- March 9, 2018
- Completion date
- November 24, 2021
- Enrollment
- 9 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.